Protocol for an economic evaluation alongside a natural experiment to evaluate the impact of later trading hours for bars and clubs in the night-time economy in Scotland: The ELEPHANT studyNurnabi Sheikh, Houra Haghpanahan, Jim Lewsey, Colin Angus, Carol Emslie, Niamh Fitzgerald, Emma McIntosh
14 May 2025
Application of distributional cost-effectiveness analysis methodology in real-world studies: a scoping review protocolTroy Francis, Bethlehem Teshome, Aleksandra Stanimirovic, Valeria E Rac
12 May 2025
Optimising colorectal cancer screening strategies and target populations in budget-constrained regions through cost-effectiveness analysis: a case from eastern ChinaHao Li, Yun Fu, Ao Xu, Peng Zhang, Weibing Wang
2 May 2025
Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspectiveShuqiao Cheng, Bin Li, Lanhua Tang, Shao Liu, Jian Xiao
29 April 2025
Longitudinal trajectories of healthcare costs among high-need high-cost patients: a population-based retrospective cohort study in British Columbia, CanadaLogan Trenaman, Daphne Guh, Kimberlyn McGrail, Mohammad Ehsanul Karim, Richard Sawatzky, Stirling Bryan, Linda C Li, Marilyn Parker, Kathleen Wheeler, Mark Harrison
25 April 2025
Informal care provision for mental versus somatic disorders in the Netherlands: a cross-sectional investigation of caregiving context and quality of life outcomesLeonarda GM Bremmers, Leona Hakkaart-van Roijen, Carin A Uyl-de Groot, Isabelle N Fabbricotti
25 April 2025
Estimating the clinical and healthcare burden of metabolic dysfunction-associated steatohepatitis in England: a retrospective cohort study using routinely collected healthcare data from 2011 to 2020Jennifer A Davidson, Hannah R Brewer, Caoimhe T Rice, Sara J Carvalho, Yestle Kim
23 April 2025
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payersCan Jiang, Kexun Zhou, Pei Shu
23 April 2025
Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer’s diseaseXiaomo Xiong, Gang Lv, Jacob Jordan King, Minghui Li, Jing Yuan, Z Kevin Lu
17 April 2025
Cost savings of a nationwide project preventing healthcare-associated infections in adult, paediatric and neonatal critical care settings in Brazil: a micro-costing studyLital Moro Bass, Leonardo Henrique Fiuza de Meireles, Edgard Joseph Kiriyama, Nancy Oliveira dos Santos, Ancelmo Honorato Ferraz de Sousa, Karen Cristina da Conceição Dias Silva, Rafaela Moraes de Moura, Cristiana Martins Prandini, Guilherme Cesar Silva Dias Santos, Renata Gonsalez dos Santos, Flavia Fernanda Franco, Ademir Jose Petenate, Cristiane Maria Reis Cristalda, Claudia Garcia de Barros, Sebastian Vernal
15 April 2025